1. Combating diseases with small molecule compounds
Combating diseases with small molecule compounds
C3BIO GmbH
Confidential

2. Company concept: rational drug design
Company concept: rational drug design
Patents and exclusive world licenses on families of compounds (purines and pyrazolopyrimidines)
Extensive network of cooperation partners
Progress made in 3 indication areas: Rheumatoid arthritis, restenosis and cancer
Confidential

3.
Pyrazolopyrimidines
Roscovitine
Confidential

4. Cancer Recognized hallmarks of cancers Uncontrolled proliferation
Cancer
Recognized hallmarks of cancers
Uncontrolled proliferation
Evasion of apoptosis
Sustained angiogenesis
Genomic instability
Common target: cyclin-dependent kinases (CDKs)
AR – aminoroscovitines (libor havl)
BA - hydroxylhalogenroscovitines (maros zatlokal)
Confidential

5. Cancer Identified compounds have increased:
Cancer
Identified compounds have increased:
Activity in biochemical and cellular assays
Potency in vivo
Metabolic stability
Tumour cell migration as well as endothelial migration are specifically being investigated to prevent cancer metastasis-a number of compounds show promising results
AR – aminoroscovitines (libor havl)
BA - hydroxylhalogenroscovitines (maros zatlokal)
Confidential

6.
Restenosis
Focus is on identification of new drug candidates interfering with vascular smooth muscle cells (VSMC) proliferation
Identified compounds may be useful for anti-restenotic therapy-some of the work is published
Confidential

7.
Rheumatoid Arthritis
Concentrate on the 30-40% non-responding RA patients
New targets-neutrophils and synovial fibroblasts
Patients at early stage of disease progression
Confidential

8. Rheumatoid Arthritis: LGR1407 induces neutrophil apoptosis
Rheumatoid Arthritis: LGR1407 induces neutrophil apoptosis
Confidential

9.
Rheumatoid Arthritis: LGR1407 inhibits TNF-induced secretion of IL-8 in neutrophils
Confidential

10.
Rheumatoid Arthritis: LGR1407 inhibits proliferation of synovial fibroblasts from RA patients
Confidential

11. Molecular target had been identified Compounds are orally available
Rheumatoid Arthritis
Molecular target had been identified
Compounds are orally available
Toxicology and pharmacokinetic studies indicate a useful therapeutic window
in vivo studies successfully carried out

12. Combating diseases with small molecule compounds
Combating diseases with small molecule compounds
For more information contact
Dr. Paul Pechan, CEO
Tel:
Confidential